Conversations with industry pioneers who are shaping the future, setting trends, and creating the selective pressures driving innovation.
Filter
- Analysis & Synthesis 2
- Arts & Culture 13
- Brand Equity & Moat Construction & Customer Experience 9
- Business & Industry 27
- Deep Tech & Bio-Infrastructure & Non-Linear R&D 9
- Digital Health Platforms 3
- Education & Society 11
- Government & Policy 3
- Health & Medicine 26
- Healthcare Systems & Digital Health & Clinical Innovation 10
- High-Stakes Operations & Risk & Systemic Resilience 7
- Human Capital & Macro Policy & Systemic Evolution 10
- Legacy Disruption & Organizational Inertia 6
- Life Sciences & Biotech & Frontier Therapeutics 19
- Life Sciences & Diagnostics 3
- MedTech 4
- Media & Entertainment & Narrative Architecture 8
- Platform Strategy & Network Effects & Scalability 8
- S1 46
- S2 21
- Science & Research 27
- Sports & Recreation 11
- Sports Performance & Elite Athletics & High-Stakes Competition 7
- Technology 13
- WMIF25 20
Alzheimer’s Neuroscience • McCance Center / Rudy Tanzi
67 | Stopping Alzheimer’s Before Symptoms Start • Rudy Tanzi
Veterinary Health: Embark • Amish Desai
66 | Data Interoperability: Extracting Value from Siloed Datasets • Embark
Research & Diagnostics: Danaher • JC Gutierrez-Ramos
51 | Resolving Scale Bottlenecks Through Structural Incentive Alignment • Danaher
Platform Biotech: Alloy Therapeutics • Errik Anderson
Open Source Biotech: Building Symbiosis in the Biotech Ecosystem
Research & Diagnostics: Revvity • Prahlad Singh
42 | Strategic Divestment: Shedding Legacy Assets to Rebuild Growth • Revvity
Research & Diagnostics: Thermo Fisher Scientific • Gianluca Pettiti
36 | Owning Data Control Points: Moat Construction in Tech • Thermo Fisher Scientific
Pharmaceuticals: Sanofi • Michael Quigley
34 | R&D Capital Efficiency as an Operational Imperative • Sanofi
Medical Technology: Philips • Betsabeh Madani-Hermann
32 | Organizational Endurance: Deciphering Internal Signal vs. Noise • Philips
Platform Biotech: Mammoth Biosciences • Trevor Martin
30 | Platform Compatibility vs. Bespoke Engineering • Mammoth Biosciences
Antibody Therapeutics: Brigham and Women's Hospital • Richard Blumberg
29 | Early Path Dynamics: Initial Conditions & Long-Term Health • Brigham & Women's
Synthetic Biology: Harvard Wyss Institute • George Church
23 | Bio-Infrastructure: Refactoring Legacy Biological Code • Dr. George Church
Pediatric Gene Therapy: Mass General Hospital • Patricia Musolino
21 | Platform Standardization: Speed-to-Market in Clinical R&D • MGH
Medical Technology: Siemens Healthineers • Bernd Montag
18 | Hardware to Ecosystem Pivots: Problem Definition Over Features • Siemens
Biomedical Engineering: Moderna / MIT • Robert Langer
17 | Portfolio Theory in Deep Tech: Managing Non-Linear R&D • Dr. Robert Langer
Cell Therapies: Mass General Hospital • Allan Goldstein
14 | Disruption Dynamics: Moving from Maintenance to Biological Repair • MGH
Brain Health: Beacon Biosignals • Jacob Donoghue
12 | Continuous Data Pipelines vs. Point-in-Time Diagnostics • Beacon Biosignals
Pathology: PathAI • Andy Beck
11 | Augmenting Human Capital: Precision as a Competitive Advantage • PathAI
Molecular Diagnostics: Caris Life Sciences • David Spetzler
09 | Timing & Sequencing: Why First-Movers Lose to Precise Scalers • Caris Life Sciences
Federal Research: NHGRI • Eric Green
07 | Managing Uncertainty at Scale: Lessons from Big Science • Human Genome Project
Thank you for joining us on this journey through innovation and evolution—your curiosity fuels the conversation, and we’re grateful to our visionary guests for sharing their insights.
Subscribe on Spotify, Apple Podcasts, and YouTube Music. If you enjoy it, consider rating it 5 stars.